Pfizer Taps Blackstone For Up To $1.5bn To Fund Development Of Monthly GLP-1 Drug Berobenatide
Pfizer has secured up to $1.5bn from Blackstone to fund berobenatide, its monthly GLP-1 obesity drug, through 2028 in return for milestone payments.
Scrip - November 12, 2026

FDA Finalizes Class II Status For AI Pap Slide Tool, Dementia-Risk Software, Two Vibration Devices
FDA orders published Nov. 5 and 6 give Class II status to an AI cervical cytology system, MCI prognosis software and two vibration devices, opening the 510(k) route for similar products.
Medtech Insight - November 12, 2026

Alcon Banks On Vivity Pro To Return Implantables To Growth After US Premium IOL Share Loss
Alcon’s third-quarter sales rose 5% to $2.7bn, but implantables fell 2% as US premium IOL competition intensified. With markets growing about 3%, it is leaning on new lenses, an RxSight license and the Neurotech acquisition to outgrow them.
Medtech Insight - November 12, 2026

Merck KGaA CEO Says M&A Stays Central After Run Of Deals
While integrating the acquisitions of Bio-Techne and Silence Therapeutics is a priority at Merck KGaA, deals remain an important pillar for growth.
Scrip - November 12, 2026

UK Price Increases Accelerate, Led By Aledronate In October
Market researcher WaveData sounded the alarm bell in October as average trade prices for UK generics experienced steep rises across the board – most notably for aledronate.
Generics Bulletin - November 12, 2026

ANI Proposes Egetis Acquisition As It Continues To Bolster Its Identity As a Rare Disease Company
As ANI announces a bid to acquire Egetis, the firm's Q3 earnings report shows steady generics progress and growing momentum in the rare disease business.
Generics Bulletin - November 12, 2026

Viatris Looks Ahead To Pacira Benefits As Generics Slide In Q3
Despite a slide in generics sales in the third quarter caused in large part by a manufacturing suspension at its Nashik plant in India, Viatris is optimistic about its generics pipeline and the benefits it will gain from its pending acquisition of Pacira BioSciences.
Generics Bulletin - November 12, 2026

German Medtechs Count On Government’s Strategic Input Amid Uptick In Mood Of Industry
Germany’s medtech industry experienced a modest bounce back after a flat 2025. On the eve of Medica 2026, a new BVMed survey pointed to rising levels of confidence among members, the association’s long-serving head of communications Manfred Beeres said.
Medtech Insight - November 12, 2026

Zydus Doubles Down On High-Value Pivot; Adempas, Ibrance Generics To Add Fuel
Zydus continues a US shift to high-value specialty and expects to launch an Ibrance generic by October 2027 as it waits on the outcome of a Cabometyx appeal while deepening its biosimilars push in India.
Generics Bulletin - November 12, 2026

Bio-Thera Claims First Simponi Biosimilar Approval In China
China’s NMPA has approved Bio-Thera’s golimumab biosimilar Ashuli for rheumatoid arthritis and ankylosing spondylitis, which the firm says is the country’s first rival to J&J’s Simponi.
Generics Bulletin - November 12, 2026

Lenvima, Leqembi Lead Robust Mainstay Growth For Eisai In Fiscal H1
Helped by global growth for mainstays, especially in the US, and the weak yen, Eisai marked double-digit growth in the fiscal first half and is confident Leqembi for Alzheimer's will meet its growth target.
Scrip - November 12, 2026

While Other Microbiome Treatments Have Failed In IBD, MRM Health Believes It Can Succeed
Belgium's MRM Health is among the few microbiome companies still chasing the ulcerative colitis indication. Its CEO explains why he thinks a mild-to-moderate focus, single-run manufacturing and a antibiotics-free trial design give MH002 a different outcome, with Phase IIb top-line data due Q4 2027.
In Vivo - November 12, 2026

Preparing For Next Pandemic, FDA Offers Guidance For Validating Emergency Authorization Tests
FDA finalizes guidance on validating diagnostic tests for emerging pathogens during declared emergency. Allows developers to send some data after submission and use synthetic samples early in an outbreak; also covers study design, home-use testing and more.
HBW Insight - November 12, 2026